Metacrine is a clinical-stage biopharmaceutical company focused on building a pipeline of differentiated drugs to treat liver and gastrointestinal diseases. Co.'s most advanced program targets the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis. Co. has built a proprietary library of over 2,500 FXR compounds. The MTCR stock yearly return is shown above.
The yearly return on the MTCR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MTCR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|